MedTrace Logo

The Effect of the Human Regenerator Jet Device on the Quality of Life of Adult Individuals [HR-QoL]

NCT07279272 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-27

No results posted yet for this study

Summary

This cross-over single-blinded study aims to evaluate the effect of a novel cold atmospheric plasma jet-producing device, the Human Regenerator Power Jet device, for individuals who suffer from chronic stress, chronic pain, chronic fatigue, sleep disorders, and Post-COVID/Long-COVID Syndrome, all conditions that affect the QoL among adults in Greece and worldwide.

Conditions

  • Chronic Stress
  • Chronic Fatigue
  • Chronic Pain
  • Post-COVID / Long-COVID

Interventions

DEVICE

Cold Atmospheric Plasma

The Human Regenerator Jet Device CAP Effect interventions include a 30 minute exposure of the subjects, every other day, with Cold Atmospheric Plasma, a total of 10 sessions

DEVICE

Atmospheric Air

The Human Regenerator Jet Device AIR Effect interventions include a 30 minute exposure of the subjects, every other day, to Atmospheric Air, a total of 10 sessions

Sponsors & Collaborators

  • THE ENDOCRINE UNIT OF THE UNIVERSITY OF ATHENS

    collaborator UNKNOWN

  • University of Athens

    lead OTHER

Principal Investigators

  • Eumorphia Remboutsika, PhD · University Research Institute for the Study of Genetic & Malignant Disorders in Childhood

  • George P Chrousos, MD, PhD · University Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
94 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2025-07-22
Completion
2025-07-22

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07279272 on ClinicalTrials.gov